Materias dentro de su búsqueda.
Mostrando 1,481 - 1,500 Resultados de 6,219 Para Buscar '"leishmaniasis"', tiempo de consulta: 0.22s Limitar resultados
  1. 1481
    “…BACKGROUND: Leishmaniasis is endemic in many countries worldwide, with a prevalence of 12 million people infected, and an estimated annual incidence of 500 000 visceral leishmaniasis cases. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Double trouble: visceral leishmaniasis in twins after traveling to Tuscany – a case report
  2. 1482
    “…BACKGROUND: Visceral leishmaniasis (VL) is characterised by a high degree of spatial clustering at all scales, and this feature remains even with successful control measures. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The role of case proximity in transmission of visceral leishmaniasis in a highly endemic village in Bangladesh
  3. 1483
    “…BACKGROUND: Miltefosine has been used successfully to treat visceral leishmaniasis (VL) in India, but it was unsuccessful for VL in a clinical trial in Brazil. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis
  4. 1484
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A real-time PCR assay for quantification of parasite burden in murine models of leishmaniasis
  5. 1485
    “…BACKGROUND: Liposomal amphotericin B (L-amB, AmBisome®) is popular for off-label use in the treatment of cutaneous leishmaniasis (CL) using dosing of 3 mg/kg/day for days 1–5, 8, 9, or days 1–5, 10 with reported clinical cure rates of 46–84%. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    962. Cutaneous Leishmaniasis: Investigating Skin Drug Levels to Optimize Liposomal Amphotericin Dosing
  6. 1486
    “…BACKGROUND: The management of visceral leishmaniasis (VL) in HIV-infected patients is often complex with patients experiencing higher mortality rates, more toxic side effects and a higher possibility of treatment failure and relapse than HIV-negative individuals with VL. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Two cases of relapsed HIV-associated visceral leishmaniasis successfully treated with combination therapy
  7. 1487
    “…OBJECTIVE: Based on studies in India (as there was no studies from outside India) amphotericin B deoxycholate has been considered as a backup drug for treatment of visceral leishmaniasis. However, treatment response and adverse effect to anti-leishmanial drugs may vary across different populations and in Bangladesh the effect to amphotericin B deoxycholate for treatment of visceral leishmaniasis is still unknown. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
  8. 1488
    “…Visceral leishmaniasis (VL) remains a serious public health problem in China. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Spatiotemporal Variation and Hot Spot Detection of Visceral Leishmaniasis Disease in Kashi Prefecture, China
  9. 1489
    “…BACKGROUND: Cytokines play a vital role in the host immune response to infection by initiating the healing process and/or accelerating the progression of the disease in cutaneous leishmaniasis (CL). Very little evidence is available on cytokine profiles and their regulatory function in CL patients in Sri Lanka. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Assessment of intralesional cytokine profile of cutaneous leishmaniasis caused by Leishmania donovani in Sri Lanka
  10. 1490
    “…METHODOLOGY: Between December 2015 and May 2017, 100 patients with localized cutaneous leishmaniasis were interviewed at a leishmaniasis referral center in Brazil. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    How cutaneous leishmaniasis and treatment impacts in the patients’ lives: A cross-sectional study
  11. 1491
    “…Leishmaniasis is a zoonotic parasitosis caused by a diphasic protozoan of the genus Leishmania. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Symptomatic Leishmaniasis in an Italian Segugio Dog from Northeastern Romania: A Case Report
  12. 1492
    “…Future implications for the American healthcare system regarding malaria and leishmaniasis are also presented.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Nonconventional opponents: a review of malaria and leishmaniasis among United States Armed Forces
  13. 1493
    “…BACKGROUND: Visceral Leishmaniasis (VL) is an infectious disease that is a significant cause of death among infants aged under 1 year and the elderly in Brazil. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of three recombinant proteins for the development of ELISA and immunochromatographic tests for visceral leishmaniasis serodiagnosis
  14. 1494
    “…INTRODUCTION: Leishmaniasis is a vector-borne infection endemic in 98 countries. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Imported cutaneous leishmaniasis: a 13-year experience of a Polish tertiary center
  15. 1495
    “…BACKGROUND: Human cutaneous leishmaniasis (CL) is an endemic disease in many parts of Sudan. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    An outbreak of cutaneous leishmaniasis among a displaced population in North Sudan: Review of cases
  16. 1496
    “…The cutaneous leishmaniasis (CL) is a most common form of leishmaniasis and it remains to be a major public health issue in Saudi Arabia. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prevalence of Leishmania species among patients with cutaneous leishmaniasis in Qassim province of Saudi Arabia
  17. 1497
    “…We aimed to identify serological, immunological and genetic markers for progression from L. donovani infection to clinical Visceral Leishmaniasis (VL). METHODS: We enrolled all residents >2 years of age in 27 VL endemic villages in Bihar (India). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Determinants for progression from asymptomatic infection to symptomatic visceral leishmaniasis: A cohort study
  18. 1498
    “…BACKGROUND: Visceral Leishmaniasis (VL) is caused by a protozoan parasite Leishmania donovani that is transmitted to humans by an infected female sandfly, Phlebotomus argentipes. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Molecular evidence supports the expansion of visceral leishmaniasis towards non-program districts of Nepal
  19. 1499
    “…However, the prophylactic role of IL-17 in visceral leishmaniasis has still not been validated. In the present study, we evaluated the prophylactic efficacy of IL-17A and interferon (IFN)-γ in Leishmania donovani-challenged Balb/c mice. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prophylactic interferon-γ and interleukin-17 facilitate parasite clearance in experimental visceral leishmaniasis
  20. 1500
    “…Leishmaniasis is caused by protozoan parasites of the genus Leishmania and is a major health problem in various parts of the world. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A clinical study of cutaneous leishmaniasis in a new focus in the Kurdistan region, Iraq
Herramientas de búsqueda: RSS